Llwytho...
Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
Two open‐label studies assessed the safety, tolerability, and pharmacokinetics of Oxbryta (voxelotor) in subjects with hepatic or renal impairment. Eight subjects with severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m(2)) and 8 healthy age‐, sex‐, and body mass index...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Clin Pharmacol |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7984382/ https://ncbi.nlm.nih.gov/pubmed/33084052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1757 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|